Published in Nat Biotechnol on June 01, 1999
Mesothelin targeted cancer immunotherapy. Eur J Cancer (2007) 2.54
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res (2009) 2.17
Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev (2004) 1.55
Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res (2014) 1.48
Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther (2012) 1.47
A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci U S A (2005) 1.37
Engineering the variable region of therapeutic IgG antibodies. MAbs (2011) 1.33
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci U S A (2006) 1.30
Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog (2008) 1.27
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther (2012) 1.27
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc Natl Acad Sci U S A (2014) 1.23
Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res (2013) 1.16
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res (2005) 1.14
The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem (2013) 1.12
By-passing selection: direct screening for antibody-antigen interactions using protein arrays. Nucleic Acids Res (2000) 1.09
A compact phage display human scFv library for selection of antibodies to a wide variety of antigens. BMC Biotechnol (2009) 1.08
A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer (2011) 1.06
Specific secretion of active single-chain Fv antibodies into the supernatants of Escherichia coli cultures by use of the hemolysin system. Appl Environ Microbiol (2000) 1.03
Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A (2002) 1.03
Phage display mediated immuno-PCR. Nucleic Acids Res (2006) 0.94
Development of a novel mammalian cell surface antibody display platform. MAbs (2010) 0.94
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer (2011) 0.91
Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. Int J Cancer (2010) 0.90
Mesothelin Immunotherapy for Cancer: Ready for Prime Time? J Clin Oncol (2016) 0.88
A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther (2013) 0.88
Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs (2011) 0.87
Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs (2012) 0.87
Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights. J Biol Chem (2012) 0.84
Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms. MAbs (2015) 0.83
Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. MAbs (2013) 0.81
Humanization of antibodies using heavy chain complementarity-determining region 3 grafting coupled with in vitro somatic hypermutation. J Biol Chem (2013) 0.81
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy. Proc Natl Acad Sci U S A (2005) 0.81
In vitro antibody affinity maturation targeting germline hotspots. Methods Mol Biol (2009) 0.81
The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan. MAbs (2011) 0.80
Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding. Proc Natl Acad Sci U S A (2017) 0.79
Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.78
Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice. PLoS One (2013) 0.78
Expression and identification of recombinant soluble single-chain variable fragment of monoclonal antibody MC3. World J Gastroenterol (2002) 0.78
Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties. Biochim Biophys Acta (2003) 0.78
Effective Optimization of Antibody Affinity by Phage Display Integrated with High-Throughput DNA Synthesis and Sequencing Technologies. PLoS One (2015) 0.77
Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins. Mol Cancer Ther (2016) 0.77
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. Clin Cancer Res (2016) 0.77
Overcoming a species-specificity barrier in development of an inhibitory antibody targeting a modulator of tumor stroma. Protein Eng Des Sel (2016) 0.77
Structural features of interfacial tyrosine residue in ROBO1 fibronectin domain-antibody complex: Crystallographic, thermodynamic, and molecular dynamic analyses. Protein Sci (2015) 0.76
Development of novel drug delivery systems using phage display technology for clinical application of protein drugs. Proc Jpn Acad Ser B Phys Biol Sci (2016) 0.75
Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using atomic force microscopy. Nanomedicine (2008) 0.75
The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy. Curr Allergy Asthma Rep (2016) 0.75
Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells. Proc Natl Acad Sci U S A (2015) 0.75
Directed evolution of human scFvs in DT40 cells. Protein Eng Des Sel (2015) 0.75
Investigational approaches for mesothelioma. Front Oncol (2011) 0.75
The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A (1982) 20.55
Cyclic AMP receptor protein of E. coli: its role in the synthesis of inducible enzymes. Proc Natl Acad Sci U S A (1970) 13.26
Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem (1993) 10.95
Pleiotropic deficiency of carbohydrate utilization in an adenyl cyclase deficient mutant of Escherichia coli. Biochem Biophys Res Commun (1969) 9.20
Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 8.53
Cyclic adenosine 5'-monophosphate in Escherichia coli. Bacteriol Rev (1976) 7.55
Regulation of beta-galactosidase synthesis in Escherichia coli by cyclic adenosine 3',5'-monophosphate. J Biol Chem (1968) 7.54
Cyclic adenosine monophosphate in bacteria. Science (1970) 7.53
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A (1987) 7.38
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol (1999) 6.62
Direct visualization of binding, aggregation, and internalization of insulin and epidermal growth factor on living fibroblastic cells. Proc Natl Acad Sci U S A (1978) 6.59
Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A (1987) 5.65
Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus. Cell (1980) 5.51
Restoration of several morphological characteristics of normal fibroblasts in sarcoma cells treated with adenosine-3':5'-cyclic monphosphate and its derivatives. Proc Natl Acad Sci U S A (1971) 5.31
Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J Biol Chem (1980) 5.24
Structure of the promoter for chicken alpha 2 type I collagen gene. Proc Natl Acad Sci U S A (1981) 4.89
In vitro transcription of the gal operon requires cyclic adenosine monophosphate and cyclic adenosine monophosphate receptor protein. J Biol Chem (1971) 4.58
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A (1987) 4.43
Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell (1980) 4.35
Cell surface protein partially restores morphology, adhesiveness, and contact inhibition of movement to transformed fibroblasts. Proc Natl Acad Sci U S A (1976) 4.32
Localization of the ASV src gene product to the plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell (1979) 4.30
Cyclic 3'5-AMP: stimulation of beta-galactosidase and tryptophanase induction in E. coli. Biochem Biophys Res Commun (1968) 4.16
Identification of two lysosomal membrane glycoproteins. J Cell Biol (1985) 4.08
Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci U S A (1985) 4.08
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 3.93
Collection of insulin, EGF and alpha2-macroglobulin in the same patches on the surface of cultured fibroblasts and common internalization. Cell (1978) 3.90
The receptosome: an intermediate organelle of receptor mediated endocytosis in cultured fibroblasts. Cell (1980) 3.88
Regulation of inducible enzyme synthesis in Escherichia coli by cyclic adenosine 3', 5'-monophosphate. J Biol Chem (1969) 3.86
Levels of translatable mRNAs for cell surface protein, collagen precursors, and two membrane proteins are altered in Rous sarcoma virus-transformed chick embryo fibroblasts. Proc Natl Acad Sci U S A (1977) 3.80
Lac DNA, RNA polymerase and cyclic AMP receptor protein, cyclic AMP, lac repressor and inducer are the essential elements for controlled lac transcription. Nat New Biol (1971) 3.79
The collagen gene: evidence for its evolutinary assembly by amplification of a DNA segment containing an exon of 54 bp. Cell (1980) 3.66
Promoter region of the human Harvey ras proto-oncogene: similarity to the EGF receptor proto-oncogene promoter. Science (1985) 3.59
Cyclic AMP levels in fibroblasts: relationship to growth rate and contact inhibition of growth. Biochem Biophys Res Commun (1971) 3.58
Cyclic AMP regulates catabolite and transient repression in E. coli. Nature (1969) 3.42
Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (1992) 3.41
Glucose depletion accounts for the induction of two transformation-sensitive membrane proteinsin Rous sarcoma virus-transformed chick embryo fibroblasts. Proc Natl Acad Sci U S A (1977) 3.26
Regulation of lac mRNA synthesis in a soluble cell-free system. Nat New Biol (1971) 3.25
Isolation and characterization of myosin from cloned mouse fibroblasts. Proc Natl Acad Sci U S A (1972) 3.24
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet (1985) 3.23
Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science (1986) 3.22
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A (1986) 3.19
A key role of starburst amacrine cells in originating retinal directional selectivity and optokinetic eye movement. Neuron (2001) 3.18
Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res (1985) 3.15
The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem (1987) 3.13
Effect of adenosine 3',5'-monophosphate analogues on the activity of the cyclic adenosine 3',5'-monophosphate receptor in Escherichia coli. J Biol Chem (1972) 3.08
The major cell surface glycoprotein of chick embryo fibroblasts is an agglutinin. Proc Natl Acad Sci U S A (1975) 3.06
Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science (1984) 3.06
Microfilament bundles and cell shape are related to adhesiveness to substratum and are dissociable from growth control in cultured fibroblasts. Cell (1977) 2.99
Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem (1986) 2.93
Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell (1987) 2.93
The role of the lac promotor locus in the regulation of beta-galactosidase synthesis by cyclic 3',5'-adenosine monophosphate. Proc Natl Acad Sci U S A (1968) 2.92
The visualization of fluorescent proteins in living cells by video intensification microscopy (VIM). Cell (1978) 2.89
HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 2.87
Regulation of cell growth by cyclic adenosine 3',5'-monophosphate. Effect of cell density and agents which alter cell growth on cyclic adenosine 3',5'-monophosphate levels in fibroblasts. J Biol Chem (1972) 2.85
Multiple-drug resistance in human cancer. N Engl J Med (1987) 2.76
Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell (1983) 2.74
Effect of Rho on transcription of bacterial operons. Nat New Biol (1973) 2.74
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
The multidrug transporter, a double-edged sword. J Biol Chem (1988) 2.61
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature (1988) 2.55
Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem (1993) 2.52
Induction of two transformation-sensitive membrane polypeptides in normal fibroblasts by a block in glycoprotein synthesis or glucose deprivation. Cell (1977) 2.52
Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer (1992) 2.50
Unusual features in the nucleotide sequence of a cDNA clone derived from the common region of avian sarcoma virus messenger RNA. Proc Natl Acad Sci U S A (1980) 2.45
ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci U S A (1988) 2.44
alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A (1997) 2.43
Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells. Proc Natl Acad Sci U S A (1984) 2.42
Amines inhibit the clustering of alpha2-macroglobulin and EGF on the fibroblast cell surface. Nature (1979) 2.41
Clostridium barkeri sp. n. J Bacteriol (1972) 2.38
Unusual methylation pattern of the alpha 2 (l) collagen gene. Cell (1982) 2.36
Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. Nature (1984) 2.36
P-glycoprotein and multidrug resistance. Curr Opin Genet Dev (1996) 2.33
Genetic analysis of the multidrug transporter. Annu Rev Genet (1995) 2.29
Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet (1986) 2.27
Quantitative determination of the lateral diffusion coefficients of the hormone-receptor complexes of insulin and epidermal growth factor on the plasma membrane of cultured fibroblasts. Proc Natl Acad Sci U S A (1978) 2.26
Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol (2000) 2.24
alpha 2-macroglobulin adsorbed to colloidal gold: a new probe in the study of receptor-mediated endocytosis. J Cell Biol (1981) 2.19
Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A (1984) 2.18
Isolation and characterization of overlapping genomic clones covering the chicken alpha 2 (type I) collagen gene. Proc Natl Acad Sci U S A (1980) 2.18
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 2.13
Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res (1986) 2.12
Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci U S A (1990) 2.12
Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc Natl Acad Sci U S A (1984) 2.11
Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell (1983) 2.11
Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A (1997) 2.10
ACTH receptors in the adrenal: specific binding of ACTH-125I and its relation to adenyl cyclase. Proc Natl Acad Sci U S A (1970) 2.09
Binding of the Sp1 transcription factor by the human Harvey ras1 proto-oncogene promoter. Science (1986) 2.08
Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci U S A (1986) 2.08
Use of recombinant plasmids to characterize collagen RNAs in normal and transformed chick embryo fibroblasts. J Biol Chem (1979) 2.07
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem (1990) 2.04
Regulation of cell motility by cyclic AMP. Nature (1972) 2.03
Correlation between splicing sites within an intron and their sequence complementarity with U1 RNA. Cell (1980) 2.02
Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell (1989) 2.00
Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem (1987) 1.99
Repression of beta-galactosidase synthesis by glucose in phosphotransferase mutants of Escherichia coli. Repression in the absence of glucose phosphorylation. J Biol Chem (1969) 1.99
High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res (1986) 1.98
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol (2000) 1.95
Activation of transcription at specific promoters by glycerol. J Biol Chem (1974) 1.95
Characterization of a major fibroblast cell surface glycoprotein. Biochemistry (1977) 1.92